Skip to main content

Table 6 Association between genotypes of MMP9, 2 and 3 and SCLC patients' survival of CAPUA study

From: Genetic polymorphisms in MMP 2, 9 and 3genes modify lung cancer risk and survival

Genotypes Patients Deaths MST
(months)
Crude HR 95% CI HRa 95% CI
MMP9 n = 129       
C/C 98 88 9.5 1.00   1.00  
C/T 28 25 8.9 1.08 0.69-1.69 1.06 0.67-1.68
T/T 3 3 24.5 0.67 0.21-2.12 0.97 0.29-3.25
MMP2 n = 140       
C/C 112 102 8.8 1.00   1.00  
C/T 27 24 8.9 0.90 0.58-1.41 0.98 0.60-1.58
T/T 1 1 9.2 1.34 0.19-9.70 1.25 0.17-9.31
MMP3 n = 116       
6A/6A 37 34 7.6 1.00   1.00  
6A/5A 61 54 9.4 0.84 0.55-1.30 0.79 0.50-1.26
5A/5A 18 16 13.4 0.69 0.37-1.26 0.67 0.35-1.27
  1. aAdjusted by age, gender, pack-years, histological type, clinical stage, surgical operation and radio and chemotherapy
  2. MST: median survival time